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Abstract  15 
Marfan syndrome (MFS) is a heritable connective tissue disorder caused by 16 
mutations in fibrillin-1, an extracellular matrix protein. To investigate the 17 
pathogenesis of aortic aneurysms in MFS, we have generated the first 18 
vascular model derived from human induced pluripotent stem cells (hiPSC). 19 
Our MFS-hiPSC derived smooth muscle cells (SMC) accurately recapitulated 20 
the pathology seen in Marfan aortas, including defects in fibrillin-1 21 
accumulation, extra-cellular matrix degradation, TGF-β signaling, contraction, 22 
and apoptosis; abnormalities are corrected by CRISPR-editing of the fibrillin-1 23 
mutation. TGF-β inhibition rescued abnormalities in fibrillin-1 accumulation 24 
and matrix metalloproteinase expression. However, only the non-canonical 25 
p38 pathway regulated SMC apoptosis, a pathological mechanism also 26 
governed by KLF4. This model has allowed us to dissect the molecular 27 
mechanisms of MFS, to identify novel targets for treatment, such as p38 and 28 
KLF4, and has provided an innovative human platform for the testing of new 29 
drugs.  30 
31 
Introduction 32 
Marfan syndrome (MFS) is a heritable autosomal dominant multi-system 33 
disorder of connective tissue affecting 1 in 5,000 individuals1–4. Premature 34 
death is due to the development of thoracic aortic aneurysm (TAA); a 35 
potentially devastating process that can progress to aortic dissection or 36 
rupture without prior symptoms4. There are currently no effective medical 37 
treatments and only surgical replacement of the aortic root increases life 38 
expectancy in patients with MFS5.   39 
MFS is caused by mutations in the fibrillin-1 (FBN1) gene, which encodes a 40 
major constituent of microfibrils found in the extracellular matrix (ECM)6,7. 41 
Fibrillin-1 interacts with and controls the bioavailability of TGF-, a potent 42 
cytokine that regulates proliferation, differentiation, ECM modeling and 43 
apoptosis8–10. Studies in a mouse model for MFS indicated that enhanced 44 
activation of the non-canonical (ERK-mediated) TGF- pathway is the 45 
principal driver of TAA progression11,12. In particular, these studies showed 46 
that losartan, an angiotensin II receptor type 1 (AGTR1) blocker, reduced 47 
AGTR1-induced TGF-β activity and mitigated TAA in MFS mice.  48 
However, the precise functional role of TGF- in aneurysm development 49 
remains controversial13,14. Indeed, recent studies in mice have exposed the 50 
complexity of TGF- signaling in MFS, by showing that both TGF-canonical 51 
and non-canonical pathways contribute to aneurysm growth and that TGF-52 
exerts both protective and detrimental effects15. The complex pleiotropic role 53 
of TGF-in aortic remodeling may also account in part for the finding that in a 54 
recent clinical trial, losartan showed no benefit over the -blocker atenolol in 55 
regulating the rate of aortic dilatation16.  56 
Currently, most of our knowledge of MFS pathogenesis has been gained from 57 
studies in animal models, including Fbn1mgR/mgR and Fbn1C1039G/+ mice11,17–19. 58 
However, the emergence of human induced pluripotent stem cells (hiPSC) for 59 
disease modeling20 provides an opportunity to use a new approach to study 60 
both the early development and disease pathology of MFS on a susceptible 61 
human genetic background.  62 
Here we describe the generation of the first vascular human model of MFS. 63 
Patient-derived hiPSC lines are differentiated into embryonic lineage-specific 64 
smooth muscle cells (SMC)21 that reliably phenocopy the aortic pathology in 65 
patients with MFS. Importantly, our study demonstrates that at an early stage 66 
TGF- appears to contribute to the developing MFS phenotype but at later 67 
stages, blockade of TGF- signaling by using losartan is ineffective in averting 68 
SMC death. In contrast, using our human MFS-SMC model, we highlight a 69 
previously undocumented role for p38-MAP kinase in regulating SMC 70 
apoptosis and proliferation, and identify Kruppel-like factor 4 (KLF4) as a new 71 
potential contributing factor to MF pathology.  72 
73 
Results 74 
MFS-specific hiPSCs and differentiation into SMC lineages 75 
To generate hiPSCs, human dermal fibroblasts from two MFS patients 76 
carrying known pathogenic mutations in the FBN1 gene and severe aortic 77 
disease were used (Supplementary Table 1). The first line, MFC1242Y, carries a 78 
missense mutation in exon 30 (3725G>A)22 representing the commonest type 79 
of Marfan-causing mutation, namely a cysteine substitution in an EGF 80 
domain23. The second line, MFG880S, harbors a missense mutation in exon 21 81 
(2638G>A) leading to a glycine-to-serine substitution24. Genomic DNA 82 
sequencing confirmed the specific FBN1 mutations (Fig. 1a and 83 
Supplementary Fig. 1a). We established two sub-clonal hiPSC lines for each 84 
MFS line. Three wild-type hiPSC lines from healthy individuals were used as 85 
controls (Supplementary Table 1) and all the results represent the average of 86 
these three lines (WT).  87 
We confirmed that hiPSC lines expressed the human pluripotency-associated 88 
gene products and that they were karyotypically normal (Fig. 1b and 89 
Supplementary Fig. 1b-d). MFS hiPSC pluripotency was assessed by 90 
differentiation into all three embryonic germ layers (Supplementary Fig. 1e,f) 91 
and by teratoma formation in vivo (Supplementary Fig. 1g).  92 
hiPSC were then differentiated into the three embryonic origin-specific SMC 93 
lineages as previously described (Fig. 1c, Supplementary Fig. 2a,b) 21,25. The 94 
SMCs were then passaged and matured in 10% serum-containing media for 95 
periods ranging from one to three months (S30). Neuroectoderm was 96 
generated as described previously26 and then trypsinized to single cells and 97 
passaged up to 12 times to generate neural crest-like cells (NC; Serrano F, 98 
Bernard WG, Granata A, Iyer D, Kim M, Gambardella L, and Sinha S; in 99 
submission). Similar to the mesoderm intermediates, NC were differentiated 100 
to SMC and allowed to mature in serum-containing medium (Supplementary 101 
Fig. 2). The intermediate populations were characterized for expression of 102 
specific markers respectively of lateral mesoderm, paraxial mesoderm and 103 
NC cells at both mRNA and protein level (Supplementary Fig. 2a-b). In 104 
response to TGF-1 and PDGF-BB treatment, the expression of these 105 
intermediate markers was downregulated while the levels of specific SMC 106 
markers, including CNN1 and MHY11 increased (Supplementary Fig. 2a). 107 
 108 
Abnormal fibrillin-1 deposition and increased TGF-  109 
After a month in serum-containing media, extracellular fibrillin-1 deposition 110 
appeared irregular and less abundant in MFC1242Y LM-, PM- and NC-derived 111 
SMC compared to equivalent WT SMC subtypes by immunofluorescence 112 
(Fig. 1d). Abnormal organization of fibrillin-rich microfibrils in MFC1242Y ECM 113 
was confirmed by transmission electron microscopy (Fig. 1e and 114 
Supplementary Fig. 3). Fibrillin-1 immuno-staining showed that the phenotype 115 
was more severe in MFC1242Y NC-SMC in comparison with SMC of LM- and 116 
PM- origins (Fig. 1f). A similar phenotype was observed for MFG880S NC-SMC 117 
(Supplementary Fig. 4a,b). By showing a stronger phenotype, SMC of NC 118 
origin appeared to be more affected by the mutant fibrilllin-1. This is largely 119 
consistent with the clinical distribution of aneurysms, which occur 120 
preferentially in the aortic root, ascending aorta and arch, regions populated 121 
predominantly by NC-derived SMC. Importantly, neither MF mutation, both of 122 
which result in an amino acid substitution, affected fibrillin-1 synthesis 123 
(Supplementary Fig. 4c-d).  124 
In MFS, abnormal fibrillin-1 may lead to excessive release of TGF- from the 125 
ECM 9. Accordingly, we measured TGF-1 in the WT and MFC1242Y SMC 126 
supernatants by ELISA. There were increased TGF-1 levels in all MFC1242Y 127 
SMC populations compared with the WT and this increase was greatest in the 128 
supernatant of NC-derived MFC1242Y SMC (Fig. 1g). Equally, MFG880S NC-129 
SMC also showed higher TGF-1 levels (Supplementary Fig. 4e).  130 
Consistent with these observations, TGF-1 protein, extracted from SMC and 131 
extracellular matrix, was increased in MFC1242Y and MFG880S NC-SMC 132 
compared with WT and the two other lineages (Fig. 1h). TGF-1 mRNA levels 133 
did not significantly differ in WT and MF SMC lineages, suggesting that 134 
increased protein levels were due to increased accumulation in the ECM 135 
(Supplementary Fig. 4f). We observed increased mRNA levels of 136 
plasminogen activator inhibitor-1 (PAI-1), a known target of TGF-1 signaling 137 
27, and of a range of matrix metalloproteinases (MMPs) in MFC1242Y SMC, 138 
especially in the NC subtype (Fig. 1i,j). Data supporting higher TGF-1 139 
activity in MFC1242Y and MFG880S NC-SMC were obtained by measuring the 140 
luciferase signal in Mink Lung Epithelial Cells stably transfected with human 141 
PAI-1 luciferase reporter and incubated with NC-SMC conditioned media 142 
(Supplementary Fig. 4g). 143 
 144 
MFC1242Y NC-SMC recapitulate the MFS aortic phenotype  145 
Our MFS hiPSC-derived SMC model allows us to observe changes in the NC-146 
SMC phenotype from an early stage of development (PTD12) to a more 147 
mature stage (S30), which may reflect the disease progression occurring in 148 
MFS patients28.  149 
We observed morphological differences between WT and MFC1242Y NC-SMC 150 
following prolonged culture in serum-containing media (S30), with WT NC-151 
SMC appearing spindle shaped while MFC1242Y NC-SMC were larger and 152 
more stellate in appearance (Fig. 2a). mRNA analysis showed increased SM 153 
markers in MFC1242Y NC-SMC at S30 versus WT NC-SMC (Fig. 2a,b). 154 
Furthermore, the proliferative capacity of both MFC1242Y NC-SMC clones 155 
decreased dramatically during maturation, compared with WT (Fig. 2c,d). 156 
Similar morphology and behavior were observed in MFG880S NC-SMC 157 
(Supplementary Fig. 5a,b). Moreover, MFC1242Y NC-SMC displayed higher 158 
poly-caspase activity at an early stage (PTD12); while at a more mature 159 
stage, MFS NC-SMC showed a higher incidence of cell death in both mutant 160 
lines compared to WT NC-SMC, consistent with increased SMC loss in MFS 161 
aortic dilatation (Fig. 2e; Supplementary Fig. 5c).  162 
MFC1242Y NC-SMC demonstrated reduced contractility in response to 163 
stimulation with the cholinergic agent, carbachol (Fig. 2f,h). The intracellular 164 
calcium responses of WT and both lines of MFS NC-SMC were also 165 
remarkably different, with WT NC-SMC generating robust cyclic calcium 166 
waves, while MFS NC-SMC cells showed equivalent initial calcium release 167 
upon carbachol treatment as the WT but failed to generate propagating 168 
calcium waves and returned abruptly to basal levels (Fig. 2g,i; Supplementary 169 
Fig. 5d and Supplementary material movie1 and 2). Similar contraction and 170 
Ca2+ flux abnormalities were previously seen in the C1039G mouse 171 
model29,30. Together these observations indicate that MFS NC-SMC show 172 
functional changes typical of those observed in the aortas of Marfan patients 173 
31,32. 174 
 175 
TGF- signaling and cyclic stretching in MFC1242Y model  176 
The MFS mouse model has implicated both TGF-β canonical and non-177 
canonical (ERK-mediated) signaling pathways in contributing to the progress 178 
of the Marfan phenotype 11. We used our human in vitro model to dissect 179 
TGF-β pathways at both early and mature stages. We observed that 180 
phosphorylated levels of a TGF-β canonical signaling component, such as P-181 
SMAD2, and non-canonical components, including P-ERK1/2 and P-p38, 182 
were increased in MFC1242Y and MFG880S NC-SMC at PTD12 stage compared 183 
to WT, while no differences were detected between WT and MF fibroblast 184 
lines (Fig. 3a,b and Supplementary Fig. 6a). At stage S30, the increase in 185 
ERK1/2 phosphorylation levels was no longer detectable while P-p38 and P-186 
SMAD2 levels remained elevated (Fig. 3b). These findings are consistent with 187 
recent observations of developmental stage-dependent differences in 188 
signaling in the MF mouse15.  189 
When we looked at the transcriptional levels of MMPs, downstream targets of 190 
TGF-β signaling, we observed that while fibroblast lines did not show 191 
significant differences (Supplementary Figure 6b), MMPs expression levels 192 
were increased in both MF NC-SMC mutants at PTD12 (Supplementary Fig. 193 
6c) and at mature stages (S30; Fig. 3c). The tissue specific inhibitors of 194 
MMPs (TIMPs), showed a biphasic expression pattern with increased 195 
expression at an early stage (Supplementary Fig. 6d), but with lower TIMP 196 
expression levels at S30 than in WT (Fig. 3d) suggesting increasing 197 
proteolysis with prolonged culture. To confirm increased MMP activity in the 198 
MF NC-SMC at S30, we also performed a FITC-gelatin degradation 199 
experiment, which showed extensive proteolytic activity in MF NC-SMC 200 
compared to the WT (Fig. 3e,f, Supplementary Fig. 6e).  201 
 202 
SMC cyclic stretch exacerbates the MF phenotype  203 
WT and MF SMC were mechanically stretched for 24h using 10% cyclic 204 
stretching at 1Hz to mimic aortic hemodynamic forces. After 24h, both WT 205 
and MFC1242Y NC-SMC were aligned parallel to the direction of the stretch 206 
(Fig. 4a). SM markers showed increased expression in MFC1242Y NC-SMC 207 
(Fig. 4b). Also, MMP9 and MMP10 were significantly increased in MFC1242Y 208 
NC-SMC in response to stretching (Fig 4c). Furthermore, we observed that 209 
Collagen type I (COL-1) expression and deposition were higher in MF NC-210 
SMC compared to WT and further increased upon stretching (Fig. 4d-e), 211 
which may lead to greater stiffness of the ECM33. Moreover, we observed 212 
increased binding of phalloidin-FITC and immunostaining for Vinculin in 213 
MFC1242Y SMC in static conditions compared to WT, which were both further 214 
incremented after stretching, suggesting that MFC1242Y SMC have higher 215 
density of stress-fibres (Phalloidin) and focal adhesions (Vinculin) than WT 216 
SMC (Fig. 4f-h). Remarkably, we also observed higher expression of p38 in 217 
MFC1242Y SMC in response to cyclic stretch at both mRNA and protein levels 218 
(Fig. 4i,j). 219 
 220 
Effect of general TGF-inhibition on the MF phenotype 221 
To test whether TGF-β signaling may have different roles at different stages 222 
of NC-SMC development, both WT and MFC1242Y NC-SMC cells were treated 223 
with anti-TGF- neutralizing antibody and Losartan, a specific AGTR1 blocker 224 
(Supplementary Fig. 7a). In mature NC-SMC cells (S30), both treatments 225 
promoted fibrillin-1 accumulation in MFC1242Y NC-SMC (Fig. 5a,b), associated 226 
with reduced canonical TGF- activity, as measured by transfecting a 4xSmad 227 
binding element (SBE4) promoter-luciferase reporter in both WT and MFC1242Y 228 
NC-SMC (Fig. 5c). Moreover, anti-TGF- blocking antibody and Losartan 229 
treatments were both able to downregulate efficiently the expression levels of 230 
MMPs and also to upregulate TIMP3 both in mature cells (S30; Fig. 5d) and 231 
at early stages (PTD12, Supplementary Fig. 7b). We therefore propose that 232 
excessive TGF- activity, through effects on MMP and TIMP expression, is 233 
responsible at least in part for the reduced amount of fibrillin-1 in MFS NC-234 
SMC. 235 
Notably, Losartan was more effective in reducing ECM degradation than 236 
Doxycycline (DOX), a nonspecific inhibitor of MMPs, suggesting losartan may 237 
be acting through additional mechanisms beyond simple MMP inhibition 238 
(Supplementary Fig. 7c,d). Extracellular fibrillin-1 only partly increased 239 
following DOX treatment, suggesting that the changes seen are consequence 240 
of abnormalities in both degradation and deposition and that mutant fibrillin-1 241 
may be more prone to proteolytic degradation than WT (Supplementary 242 
Fig.7e,f). High level of TGF-1 is likely to be caused by ECM breakdown, as it 243 
decreases upon DOX treatment (Supplementary Fig. 7g). 244 
Despite beneficial effects on fibrillin-1 deposition and matrix proteolysis, anti-245 
TGF- blocking antibody treatment failed to rescue the impaired proliferation 246 
of MFC1242Y NC-SMC, while Losartan provided partial rescue (Fig. 5e). 247 
Furthermore, the increased apoptosis seen in MFC1242Y NC-SMC was 248 
unaffected upon Losartan treatment as shown by AnnexinV analysis (Fig. 5f). 249 
Likewise, a poly-caspase assay also showed no benefit with losartan on 250 
MFC1242Y NC-SMC cell death (Supplementary Fig. 8a). 251 
Taken together, these results suggest that ECM turnover in MFS is regulated 252 
through pathways that are distinct from those regulating SMC proliferation and 253 
death. 254 
 255 
Emerging roles of p38, KLF4 and 1 integrin in MFS model 256 
To better understand the contribution of different TGF- signaling pathways in 257 
the development of the MFS phenotype, NC-SMC were treated with inhibitors 258 
of either the canonical pathway (SB431542), ERK1/2 phosphorylation 259 
(PD98059) or p38-MAP kinase (SB203580) (Fig. 6 and Supplementary Fig. 260 
9a,b). Analysis of fibrillin-1 deposition by immunostaining showed that 261 
inhibition of p38 phosphorylation was surprisingly effective in rescuing the 262 
phenotype, comparable to Losartan in both MFC1242Y and MFG880S (Fig. 6a,b 263 
and Supplementary Fig. 10a,b), while inhibition of canonical Smad signaling 264 
or ERK1/2 by SB431542 or PD98059 respectively had no significant effects 265 
(Fig. 6a,b and Supplementary Fig. 10a,b). Comparable results were found for 266 
effects on cell proliferation with significant rescue of suppressed proliferation 267 
only by the p38-MAP kinase inhibitor, SB203580 and Losartan (Fig. 6c). 268 
To investigate further the proliferative mechanisms affected in MF NC-SMC, 269 
we looked at potential regulators, including KLF4 (Krüppel-like factor 4) and 270 
observed a dramatic increase in KLF4 mRNA levels in MF lines compared to 271 
WT NC-SMC (Fig. 6d and Supplementary Fig. 11a). Both inhibition of p38 272 
upon SB203580 treatment and efficient knock-down of KLF4 using siRNA 273 
(siRKLF4) were able to increase mRNA levels of the proliferation marker, 274 
CCND1 (cyclinD1), which were significantly lower in MFC1242Y NC-SMC 275 
compared to WT (Fig. 6e). Moreover, both TP53 (tumor suppressor protein 276 
p53) and CDKN1A (p21; Cyclin-Dependent Kinase Inhibitor 1A), which 277 
promote cell cycle arrest, were upregulated in MF cells and reduced in 278 
response to SB203580 and SiKLF4 treatments  (Fig. 6f,g). Therefore, 279 
silencing KLF4 had also a positive effect on MFC1242Y and MFG880S NC-SMC 280 
proliferation (Supplementary Fig. 11b,c). Moreover, silencing of KLF4 281 
increased the deposition of fibrillin-1 in the matrix compared to the control 282 
scramble siRNA (siScr; Fig. 6h,i). 283 
Similarly to KLF4 siRNA approach, a specific inhibitor of the MEK5/ERK5 284 
pathway, BIX02189, exclusively reduced KLF4 mRNA and protein levels in 285 
MFC1242Y NC-SMC (Fig. 6j and Supplementary Fig. 11d). Conversely, 286 
SB203580 and Losartan, did not affect total KLF4 mRNA and protein levels, 287 
suggesting that p38 and KLF4 contribute independently to the same signaling 288 
pathway that controls SMC proliferation (Fig. 6j and Supplementary Fig. 11d). 289 
Consequently, inhibiting the MEK5/ERK5 pathway by BIX02189 restored 290 
normal proliferation rate and mRNA levels for TP53, CCND1 and CDKN1A in 291 
MFC1242Y NC-SMCs comparable to WT (Fig. 6c and Supplementary Fig. 11e). 292 
Notably, both SB203580 and KLF4 siRNA reduced the apoptotic activity of 293 
both MF mutant lines (Fig. 7a and Supplementary Fig. 10d). This may 294 
indicate that both p38 and KLF4 contribute to the same regulatory apoptotic 295 
mechanism, which is exclusive of SMC, since no difference in cell death was 296 
seen between WT and MF fibroblasts (Supplementary Figure 10c). Whereas, 297 
MFC1242Y NC-SMC apoptotic levels were found unchanged or increased upon 298 
Losartan and PD98059 or U0126 (selective inhibitor of MEK1/2) treatments 299 
respectively, suggesting that the ERK1/2-mediated pathway has a protective 300 
role for cell death in this model (Fig. 7a and Supplementary Fig. 12a). 301 
Moreover, MF NC-SMC apoptosis was substantially reduced in cells with 302 
plasminogen activation, implying that pericellular proteolysis is partially 303 
responsible for MF SMC death34 (Supplemental Fig. 12b). 304 
Finally, a new insight about the MF cell death mechanisms comes from the 305 
stretch studies. Upon cyclic stretching, MFC1242Y NC-SMC expressed higher 306 
levels of KLF4, CDKN1A and TP53, which may contribute to MF apoptosis 307 
(Fig. 7b). In addition, 1 integrin, an essential adhesion molecule, increased 308 
in response to cyclic stretch at both mRNA and protein levels (Fig. 7c,d). A 309 
blocking anti-1 integrin antibody specifically downregulated p38 phospho-310 
protein levels and consequently TP53 expression (Fig. 7e,f). The hypothesis 311 
that 1 integrin may play a role in promoting apoptosis, potentially mediated 312 
by p38 in MF NC-SMC is consistent with the AnnexinV study that showed 313 
decreased apoptotic levels in MF NC-SMC upon anti-1 integrin blockade 314 
(Fig. 7g). And since 1 integrin was more expressed in NC-SMC compared to 315 
the other lineages, these findings may be a potential explanation of why NC-316 
SMC are more vulnerable to fibrillin-1 mutation (Supplementary Fig. 13a,b). 317 
 318 
Correction of C1242Y mutation by CRISPR/Cas9 FBN1 editing 319 
Notably, the upregulation of both P-p38 and KLF4 observed in our hiPSC-320 
derived MFC1242Y NC-SMC model was also found in aortic sections of two 321 
patients affected by Marfan syndrome, compared to healthy individuals, 322 
validating our in vitro findings (Fig. 8a-d).  323 
To verify that the MFC1242Y hiPSC-derived SMC phenotype is caused solely by 324 
the C1242Y mutation, we generated a CRISPR/Cas9 isogenic MF hiPSC line 325 
where the nucleotides in the mutant allele were replaced with WT nucleotides, 326 
which we refer to as CRISPR MF corrected (Supplementary Fig. 14a,b). In 327 
parallel, we generated as control an isogenic CRISPR/Cas9 MF hiPSC line 328 
where the WT nucleotides were inserted in the WT allele, therefore retaining 329 
the C1242Y mutation (CRISPR MF mutant; Supplementary Fig. 14b-d). 330 
CRISPR MF corrected showed a WT fibrillin-1 phenotype compared to 331 
MFC1242Y and CRISPR MF mutant (Fig. 8e,f). In CRISPR MF corrected NC-332 
SMC, the phosphorylated levels of TGF- pathway effectors were lowered to 333 
levels comparable to WT (Fig. 8g). In addition, TGF- levels in the 334 
supernatant, the mRNA levels of MMP10, and the extent of matrix 335 
degradation of CRISPR MF corrected NC-SMC were significantly reduced 336 
(Fig. 8h and Supplementary Fig. 15a-f).  337 
In conclusion, our hiPSC-derived SMC have proven to be a robust model for 338 
MFS and a unique tool for the identification of new targets, including p38 and 339 
KLF4, which may represent novel therapeutic opportunities for MFS treatment 340 
(Fig. 8i).  341 
342 
Discussion 343 
This study describes the first Marfan Syndrome (MFS) patient-derived hiPSC 344 
model that faithfully mimics the human vascular phenotype, which is the main 345 
cause of premature death in MFS patients7. Recently, Quarto and colleagues 346 
described the MFS skeletal phenotype using a human iPSC model35. 347 
However, our model recapitulates the key aspects of MFS vascular pathology 348 
and highlights the complexity of the downstream signaling pathways 349 
identifying a key role for p38 and KLF4 in disease development. 350 
A crucial step in these studies was to generate vascular SMC of specific 351 
embryonic origins to model different aortic regions as aneurysms in MFS are 352 
found principally in the aortic root, ascending aorta and arch, regions invested 353 
by NC-SMC36,37. Interestingly, our model indicated that SMC of neural crest 354 
origin, which deposit higher levels of extracellular fibrillin-1 (Fig. 2a,b) and 355 
appear to be more proliferative when compared to the other two lineages, are 356 
most severely affected by the disease. Thus, NC-SMC appear to possess 357 
intrinsic properties, for instance differential expression of 1 integrin, that 358 
make them more susceptible to FBN1 mutations, reinforcing the importance of 359 
using lineage-specific systems for vascular disease modeling.  360 
Abnormal TGF-β activation and signaling have been documented in MFS 361 
mouse models12,19,38 and has been proposed as a common factor in MFS-362 
related disorders, such as Loeys-Dietz syndrome39–41. As TGF-β 363 
bioavailability seems to be affected by inhibition of MMP activity via 364 
Doxycycline, we suggest that increased proteolysis is responsible for high 365 
TGF-β levels detected in our MF model42. Importantly, blocking TGF-β, 366 
whether by using TGF-β neutralizing antibody or the AGTR1 blocker, 367 
Losartan, attenuated or prevented aortic root dilatation in mice43.  However, 368 
recent randomized clinical trials in patients with MFS have been disappointing 369 
with losartan showing no benefit over either placebo or beta-blockade16,44,45. 370 
The rationale for using Losartan as a TGF-β blocker is that Angiotensin II can 371 
regulate TGF-β1 mRNA and protein expression and potentially TGF-β 372 
activation46,47 and cross-talk with TGF-β signaling by promoting the 373 
phosphorylation of MAP kinases48 374 
Interestingly, in C1039G MFS mice, TGF-β-mediated ERK1/2 activation was 375 
driving aneurysm formation19. However, other studies have shown that TGF-β 376 
neutralization either exacerbated or mitigated TAA progression depending on 377 
whether the treatment was initiated before or after aneurysm formation15,49. 378 
Indeed, dual treatment with losartan and late TGF-β blockade entirely blocked 379 
aortic aneurysm development in the mgR mouse accompanied by a dramatic 380 
increase in phosphorylated ERK1/215. These findings suggest that the link 381 
between ERK1/2 phosphorylation and disease development is not simple. 382 
Interestingly, p38 activation has been documented in Fbn1-null mice (mgN) 383 
with a more severe aortic phenotype50 and systemic p38 blockade has been 384 
found to normalize P-smad2 levels in the mgN mouse.  385 
Correspondingly, we demonstrated that increased TGF-β activity in MFS SMC 386 
was associated with increased phosphorylation of endogenous SMAD2, 387 
ERK1/2 and p38 at an early stage as reported in MFS mouse models19,50, 388 
while  at a more mature stage, ERK1/2 phosphorylation reduced to WT levels, 389 
which may indicate the need for distinct therapies at different disease time-390 
points, as also suggested by Ramirez and colleagues using the mgR mouse 391 
model15.  392 
In our model, as consequence of reducing TGF-β activity, Losartan was 393 
therefore able to lower MMP expression and reduce ECM degradation when 394 
cells were treated both at PTD12 and S30 stages. However, Losartan had 395 
minimal or no effect in reducing the apoptotic activity in MF SMC (Fig. 5f).  396 
By dissecting TGF-β pathways using both canonical and non-canonical 397 
pathway inhibitors, we observed that blocking ERK1/2 aggravated the 398 
phenotype by reducing MF-SMC proliferation and increasing apoptotic rates. 399 
Conversely, p38 inhibition by SB203580, had previously unreported beneficial 400 
effects on MFC1242Y SMC proliferative ability and viability. The improved SMC 401 
viability was associated with upregulation of proliferation makers and 402 
downregulation of TP53 and P21, known to inhibit the cell cycle with a role in 403 
apoptosis51,52. Taken together, these data suggest that in this human system, 404 
there are elements of TGF- non-canonical signaling that depending on the 405 
disease stage, may have a detrimental impact, such as p38, while others, 406 
such as ERK1/2, may have a protective role in MFS pathogenesis15.  407 
Consequently, the broad upstream inhibition of TGF- signaling may not fully 408 
reverse the MF phenotype and targeting of regulatory pathways such as p38 409 
and the identification of novel targets, such as KLF453,54, may be essential.  In 410 
response to cyclic stretch, we observed a more severe phenotype in MF 411 
SMC, including upregulation of MMPs and p38, increased collagen I 412 
deposition and increases in stress fibers and focal adhesions, resembling the 413 
elevated cellular and ECM stiffness seen in SMC from Marfan patients33. 414 
These observations indicate a complexity of signaling, which may reflect 415 
additional non-TGF-β mediated mechanotransduction caused by defective 416 
fibrillin-1, as a major contributor to the phenotype55,56 and uncover 1 integrin 417 
as a potential mediator of this process. 418 
Our findings suggest that 1 integrin, which is known to interact with fibrillin-419 
157, appears to have an important role in regulation of MF SMC death, 420 
potentially through p38 as shown previously58 and may explain the 421 
susceptibility of the ascending and aortic arch to aneurysm development, 422 
since it is highly expressed in NC-derived SMC. 423 
Ultimately, the results obtained with our hiPSC-SMC in vitro model, including 424 
high levels of both KLF4 and phospho-p38 were validated in patient samples, 425 
suggesting that the in vitro system accurately models human disease.  426 
In conclusion, our model represents an innovative tool to dissect molecular 427 
and mechanosensing mechanisms of MFS and identify novel targets for 428 
potential new treatments, as well as a resourceful platform for testing new 429 
drugs.  Finally, our human lineage-specific SMC model has opened the door 430 
for the use of hiPSC harboring different FBN1 mutations to understand the 431 
mechanisms underlying genotype-phenotype variability in MFS, which will 432 
allow the development of preventative strategies and precision medicine for 433 
individual patients.   434 
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  622 
Figure 1: Generation of hiPSC and lineage-specific SMC from Marfan 623 
MFC1242Y fibroblasts show greatest perturbation of fibrillin-1 deposition, 624 
TGF- levels and MMP expression in MFC1242Y NC-SMC 625 
a) DNA sequencing analysis of MF hiPSC showing 3725G>A heterozygous 626 
mutation in FBN1 in exon 30. b) Immunofluorescence staining of MFC1242Y 627 
hiPSC colonies for the pluripotency markers, OCT3/4, SOX2, SSEA4 and 628 
TRA-1-60. Scale bar = 100 m. c) Schematic representation of hiPSC 629 
differentiation to three different smooth muscle cell (SMC) origins: lateral 630 
mesoderm (LM), paraxial mesoderm (PM) and neuroectoderm (NE)/neural 631 
crest (NC). d) Immunostaining analyses of extracellular fibrillin-1 in MFC1242Y 632 
and WT SMC of LM, PM and NC embryonic origins after 30 days of culturing 633 
in serum-containing medium (S30) (scale bar=100m). e) Transmission 634 
electron microscopy (TEM) of fibrillin-rich microfibrils (arrows) of WT and 635 
MFC1242Y NC-SMC (scale bar = 500nm). f) Quantification of fibrillin-1 staining 636 
relative to cell number in MFC1242Y and WT SMC of all three embryonic 637 
lineages. g) Levels of TGF-1 measured by ELISA in the supernatant of 638 
MFC1242Y SMC and WT SMC. h) Cropped blot of total TGF-1 in WT, MFC1242Y 639 
and MFG880S SMC lysates. I) RT-qPCR of plasminogen activator inhibitor-1 640 
(PAI-1) expression in WT and MFC1242Y LM-, PM- and NC-SMCs. j) MMP1 641 
and MMP9 mRNA levels detected in WT and MFC1242YSMC lineages. The 642 
relative mRNA level was normalized to its GAPDH/PBGD content. The results 643 
are presented as means ± SD of three independent experiments. The 644 
asterisks indicate statistically significant differences; * p< 0.05; ** p< 0.01. ns 645 
= non significant. 646 
 Figure 2: MFC1242Y hiPSC-derived SMC exhibit functional abnormalities 647 
consistent with the human disease phenotype.  648 
a) WT and MFC1242Y NC-SMC immunofluorescence staining for CNN1. b) 649 
Expression analysis of SM markers, CNN1, ACTA2, TAGLN and MYOCD at 650 
hiPSC stage, early (PTD12) and mature stage (S30) of WT and MFC1242Y NC-651 
SMC. Proliferation of MFC1242Y and WT NC-SMC at intermediate NC stage, at 652 
PTD12 and at S30 by c) MMT assay and by d) BrdU staining (at S30; scale 653 
bar=50m). Ratio of BrdU-positive cells is expressed relative to total number 654 
of cells (nuclei-DAPI staining). e) Apoptotic pathway activation measured by 655 
FAM poly-caspase flow cytometry in MFC1242Y NC-SMC and WT NC-SMC at 656 
early stage PTD12 and at S30. Cell viability assessed by PI staining. 657 
Quantification is shown in Supplemental Figure 5c.  f) Surface area of WT and 658 
MFC1242Y NC-SMC before and 3 minutes after carbachol stimulation to 659 
measure contractile ability (basal, blue line; contracted, red line). g) Ca2+ flux 660 
measured by Fluo-4AM loading and intensity of WT and MFC1242Y NC-SMC at 661 
basal (0s), stimulation with carbachol (4s), after 30s stimulation and total 662 
loading after triton (tx) treatment. h) Quantification of contractility by 663 
measuring the change in cell surface areas in MFC1242Y NC-SMC compared to 664 
WT NC-SMC (average n of cells=15). i) Single cell fluorescence tracing of WT 665 
and MFC1242Y SMC before and after carbachol stimulation (4s), relative to 666 
basal level and total Fluo-4AM loading.  667 
The results are representative of three independent experiments (means ± 668 
SD). The asterisk indicates statistically significant difference (* p< 0.05). 669 
 670 
Figure 3: Increased TGF- signaling correlates with MMP expression and 671 
matrix degradation in MFC1242Y NC-SMC. a) Cropped western blot analysis 672 
of total and phosphorylated levels of TGF- canonical (SMAD2) and non-673 
canonical (ERK1/2 and p38) pathways in WT and MFC1242Y NC-SMC at 674 
PTD12 and S30. The result is representative of three independent 675 
experiments. b) Quantification of the phosphorylated levels of SMAD2, 676 
ERK1/2 and p38 relative to the total protein levels and to -actin. c,d) RT-677 
qPCR expression profile of a selection of MMPs and TIMPs in MFC1242Y and 678 
WT NC-SMCs at S30 stage. The results for each sample were normalized to 679 
its GAPDH and PBGD content. e) FITC-gelatin degradation assay performed 680 
with WT and MFC1242Y S30 NC-SMC over 48h. Cells were then fixed and 681 
stained for the SMC marker, CNN1 (red). f) Quantification of the FITC-682 
degraded areas for S30 MFC1242Y NC-SMCs compared with WT. The results 683 
are presented as means ± SD of three independent experiments. The 684 
asterisks indicate statistically significant differences; * p< 0.05; ** p< 0.01; ***p 685 
< 0.001. ns = non significant. 686 
 687 
Figure 4: Effect of mechanical cyclic stretching on MFC1242Y SMC 688 
phenotype. a) Morphology of NC-SMC before and after cyclic stretching 689 
(Flexcell FX-5000, 10% elongation); double arrows indicate stretch 690 
directionality. RT-qPCR mRNA profile of SM markers (CNN1, ACTA2 and 691 
TAGLN, b), MMP9 and MMP10 (c) and Collagen type I (COL-1; d) in WT and 692 
MFC1242Y NC-SMC before and after 24h stretching. Immunofluorescence 693 
analysis of WT and MFC1242Y SMC before and after stretching for Collagen I 694 
(e), Phalloidin-FITC (f) and Vinculin (g). h) Quantification of Collagen type I, 695 
Phalloidin and Vinculin staining intensity relative to cell numbers in WT and 696 
MFC1242Y SMC in un-stretched and stretched conditions. i) mRNA expression 697 
levels of p38 in WT and MFC1242Y SMC before and after stretching. The 698 
asterisks indicate statistically significant differences; * p< 0.05; ** p< 0.01. j) 699 
Cropped western blot of total and phospho-protein levels for p38 in un-700 
stretched and stretched NC-SMC.  Results are presented as means ± SD of 701 
two independent experiments. 702 
 703 
Figure 5: Inhibition of TGF-- and AGTR1-mediated signaling rescues 704 
the loss of fibrillin-1 but does not rescue MFC1242Y SMC proliferation and 705 
cell death. a) Immunostaining for extracellular fibrillin-1 in S30 WT and 706 
MFC1242Y NC-SMCs following treatment with TGF- neutralizing antibody (-707 
TGF- Ab) or the AGTR1 inhibitor, Losartan. b) Quantification of fibrillin-1 708 
immunostaining expressed relative to cell numbers in control and treated 709 
samples. c) TGF- signaling activity was assessed by transiently transfecting 710 
control and treated WT and MFC1242Y NC-SMC with 4 Smad binding element 711 
(SBE4)-Luciferase reporter vector and Luciferase luminescent signal was 712 
measured after 12h. Luciferase activity expressed relative to protein 713 
concentrations. d) mRNA was extracted from control and samples treated 714 
with TGF- neutralizing antibody and Losartan. Levels of MMP1, MMP9, 715 
MMP10 and TIMP3 were detected by RT-qPCR in WT and MFC1242Y NC-716 
SMCs and e) cell proliferation was measured using an MMT assay after 48h 717 
of treatment. f) Flow cytometric staining for AnnexinV shows apoptotic levels 718 
in both MFC1242Y SMC control (red) and Losartan treated (purple) compared to 719 
WT control (blue) and treated (green).  720 
Results are presented as means ± SD of three independent experiments. The 721 
asterisks indicate statistically significant differences; * p< 0.05; ** p< 0.01. ns= 722 
non significant. 723 
 724 
Figure 6: Inhibition of p38 phosphorylation or AGTR1 and knock-down 725 
of KLF4 rescue fibrillin-1 deposition and SMC proliferation defects. a) 726 
Immunofluorescence shows fibrillin-1 staining in S30 NC-SMC after 7 days 727 
treatment with a range of inhibitors: CTL= control; SB431542 (ALK5 inhibitor); 728 
SB203580 (p38 inhibitor); PD98059 (ERK1/2 inhibitor) and Losartan (ATR1 729 
inhibitor). b) Quantification of fibrillin-1 staining relative to cell number (nuclei) 730 
using ImageJ. c) MMT assay to measure NC-SMC proliferation after 48h 731 
treatment with SB203580, BIX02189 (MK5/ERK5 inhibitor) and Losartan. d) 732 
KLF4 mRNA levels in MFC1242Y NC-SMCs and WT NC-SMC in response to 733 
KLF4 siRNA (siRKLF4) and scrambled siRNA (siScr) transfections. e) CCND1 734 
(CyclinD1) expression f) TP53 (p53 protein) expression and g) CDKN1A 735 
(P21) mRNA expression levels in MFC1242Y NC-SMC and WT in response to 736 
SB203580 and siRKLF4. h,i) Immunostaining analysis and quantification of 737 
WT and MFC1242Y NC-SMC showing fibrillin-1 deposition in response to KLF4 738 
knockdown (siRKLF4) compared to scrambled siRNA (siScr). j) Immunoblot 739 
for total KLF4 in WT and MFC1242Y NC-SMC samples transfected with 740 
siRKLF4 or treated with SB203580 (p38 inhibitor) or BIX02189 (MEK5/ERK5 741 
inhibitor).  742 
The results are presented as means ± SD of three independent experiments. 743 
The asterisks indicate statistically significant differences; * p< 0.05; ** p< 0.01.   744 
 745 
Figure 7: MFS SMC death is regulated by p38, KLF4 and 1 integrin. a) 746 
Flow cytometric staining for AnnexinV to determine apoptosis levels of WT 747 
and MFC1242Y NC-SMC following treatment with SB203580, Losartan, 748 
PD98059 (ERK1/2 inhibition) and by transfection with KLF4 siRNA.  749 
mRNA expression levels for KLF4, CDKN1A and TP53 b) and 1 integrin (c ) 750 
in un-stretched and stretched conditions in WT and MF NC-SMC. d) Flow 751 
cytometric analysis of 1 integrin-APC levels in NC-SMC before and after 752 
stretching. e) Cropped western blot for SMAD2, ERK1/2 and p38 phospho-753 
proteins in control (CTL, IgG), stretched conditions and after treatment with 754 
anti-1 integrin blocking antibody (anti-1 Ab) in WT and MFC1242Y NC-SMC. f) 755 
RT-qPCR profile of TP53 expression in control (CTL) and anti-1 Ab treated 756 
WT and MF NC-SMC. g) Comparison of apoptotic levels by AnnexinV flow 757 
cytometry in control (CTL) and upon treatment with anti-1 integrin antibody  758 
of WT and MFC1242Y NC-SMC in resting and stretched conditions.  759 
The results are presented as means ± SD of three independent experiments. 760 
The asterisks indicate statistically significant differences; * p< 0.05; ** p< 0.01.   761 
 762 
Figure 8: Correction of MF mutation in hiPSC by CRISPR/Cas9 editing 763 
rescues fibrillin-1 phenotype. a) Immunostaining of human ascending aorta 764 
sections of healthy patients and MF patients for P-p38 (green), ACTA2 765 
(magenta) and DAPI (blue). b) Quantification of P-p38 staining relative to 766 
number of ACTA2 positive SMC cells in healthy and MF aortic sections (n=2). 767 
c) Immunostaining for KLF4 (green), ACTA2 (magenta) and DAPI (blue) in 768 
aortas of healthy and MF patients. d) KLF4 staining quantification relative to 769 
the number of ACTA2 positive cells in healthy and MF aortic sections (n=2). 770 
e) Immunostaining for fibrillin-1 in S30 NC-SMC derived from MFC1242Y hiPSC, 771 
CRISPR MF mutant (MFC1242Y hiPSC CRISPR-edited with WT sequence into 772 
the WT allele), CRISPR MF corrected (MFC1242Y hiPSC CRISPR-edited with 773 
WT sequence into the mutant allele to correct the C1242Y mutation) and WT 774 
hiPSC.  f) Quantification of fibrillin-1 staining levels in the four groups depicted 775 
in e normalized for cell numbers. The asterisks indicate statistically significant 776 
differences; * p< 0.05; ** p< 0.01. g) Cropped blots of phosphorylated and 777 
total SMAD2, ERK1/2 and p38 with β-actin loading controls in S30 NC-SMC 778 
derived from MFC1242Y hiPSC, CRISPR MF mutant, CRISPR MF corrected 779 
and WT hiPSC. The result is representative of two independent experiments. 780 
h) AnnexinV assay to determine apoptotic rate in CRISPR MF corrected 781 
compared to CRISPR MF mutant. The results are presented as means ± SD 782 
of two independent experiments.  i) Schematic of the proposed mechanism 783 
for regulating SMC loss and matrix breakdown in MFS.  784 
 785 
  786 
Supplementary Material and Methods 787 
hiPSC Derivation and Culture Conditions  788 
MFC1242Y fibroblasts were purchased from Coriell cell bank (GM21943). 789 
MFG880S fibroblasts were obtained from Addenbrooke’s hospital.  790 
The generation of patient-derived hiPSC was approved by NRES Committee, 791 
Cambridgeshire (ethic code; 11/EE/0053) and informed consent was obtained 792 
from all the patients. Fibroblasts were cultured in DMEM (Sigma) with 10% 793 
FBS (Sigma), 50 U ml−1 penicillin (P) and 50 μg ml−1 streptomycin (S). To 794 
generate hiPSC, MF fibroblasts harboring FBN1 mutations were transfected 795 
using commercially available monocistronic iPSC reprogramming kit from 796 
Vectalys, consisting of four vectors encoding: OCT4, SOX2, KLF4, v-MYC; 797 
retroviral transduction was performed on 100 000 cells per one well of 6-well 798 
plate in mitotically inactive mouse embryonic fibroblasts (MEF) media without 799 
P/S per patient line. Five days post-transduction, the cells were resuspended 800 
with trypsin, and 1 × 105 cells were and seeded onto 10-cm dishes pre-plated 801 
with irradiated MEF feeders (CF-1 MEF IRR). Colonies appeared between 802 
day 12 and 32 after transfection. Colonies with hESC-like morphology were 803 
manually picked and transferred to 12-well plates pre-plated with inactivated 804 
MEF feeders containing 10μM p160ROCK (Rho-Associated coiled-coil 805 
containing Protein Kinase 1) inhibitor (Y-27632; Tocris). Two independent 806 
colonies were picked and expanded from each of the MF mutant lines. All 807 
hiPSC were maintained on irradiated mouse feeders in typical DMEM/F12 808 
medium, supplemented with 20% Knockout Serum Replacement (Gibco), 2 809 
mM L-glutamine, 0.1 mM non-essential amino acids, 0.1 mM β-810 
mercaptoethanol, and 4 ng/ml FGF-2 (R&D System). Medium was changed 811 
every day. Cells were routinely passaged using 1 mg/ml type IV collagenase 812 
(Invitrogen).  813 
Human WT hiPSC were obtained from the Cambridge Biomedical Research 814 
Centre iPS Core Facility. Marfan patient specific hiPS and control hiPS cells 815 
are referred as MF hiPSC and WT hiPSC respectively.  816 
All hiPSC lines were validated by Cambridge Biomedical Research Centre 817 
iPS Core Facility for expression of endogenous pluripotency markers versus 818 
transgenes by qPCR and by in vitro differentiation into the three germ layers. 819 
hiPSC lines were routinely tested for presence of mycoplasma contamination 820 
by Mycoplasma Experience LTD. 821 
CRISPR-mediated FBN1 gene editing 822 
i. Construction and cloning strategy of CRISPR guide RNA/CAS9 plasmid  823 
The Cas9 and single guide RNA (sgRNA) plasmid pSpCas9(BB)-2A-Puro 824 
(PX459) was obtained from Addgene (plasmid 48141). The sgRNAs targeting 825 
FBN1 gene were designed according to the rule of 5’-GN20NGG-3’ 826 
(Supplemental Table 2). sgRNAs were synthesized and ligated to the PX459 827 
plasmid that was digested with BbsI (New England Biolabs) to obtain an 828 
expression vector of Cas9 and FBN1 sgRNA. CRISPR2 guide RNA 829 
(Supplementary Table 2) was selected for targeting using Transgenomic™ 830 
Surveyor™ Mutation Detection Kit (Thermo Fisher). 831 
A fragment of genomic DNA from FBN1 containing 1063 BP upstream and 832 
970 BP downstream flanking Exon 30 was amplified by PCR with specific 833 
primers (Supplemental Table 2). This fragment was cloned into a 834 
pUC18plasmid using PstI and SacI restriction sites. To facilitate the 835 
screening, a silent mutation, which removes the putative ClaI restriction site in 836 
Exon 30, was created by directed mutagenesis (QuikChange II XL Site-837 
Directed Mutagenesis Kit, Qiagen). The piggyBac PGK-PuroR-pA cassette (a 838 
kind gift from Dr Pentao Liu) was inserted into the donor plasmid at 40bp into 839 
the intron upstream of Exon 30. This intronic location was checked with 840 
Human Splicing Finder software to avoid exon skipping59. KpnI and BclI 841 
restriction sites were then created by direct mutagenesis (QuikChange II XL 842 
Site-Directed Mutagenesis Kit, Quiagen) to generate the final donor plasmid 843 
with a selectable marker in the 5’ intronic region, the wildtype exon 30 and two 844 
intronic homology arms for HDR (Supplemental Figure 10A). 845 
ii. Gene targeting in Marfans hiPSC 846 
For gene targeting, 2.5X106 MF hiPSCs were electroporated with 1 ug each of 847 
the donor plasmid and Cas9 sgRNA plasmid (Addgene) in 82ul Lonza Stem 848 
Cell Solution  + 18 µL suplement 1 (Lonza) using CA137 program of 4D- 849 
nucleofector system (Amaxa). Transfected cells were plated onto DR4 strain 850 
feeders (Jackson Laboratory) and cultured in CDM BSA+10% KSR 851 
supplemented with 4 ng/ml FGF-2 and 10uM of Y-27632. 36 hours after 852 
transfection, puromycin selection (1g/mL) was applied and the surviving 853 
colonies were picked and expanded for PCR screening verification. Primers 854 
used are listed in Supplementary Table 2. 855 
hiPSC differentiation protocols 856 
i. 3 germ layers differentiation 857 
Differentiation assays were performed as previously described25. For 858 
differentiation into the embryonic germ layers, hiPSC were cultured in 859 
chemically defined CDM medium with 10 ng/mL Activin A (R&D system) and 860 
12 ng/mL FGF2 (R&D system) on 0.1% gelatin coated plates as described 861 
previously 60. CDM-BSA comprised Iscove’s modified Dulbecco’s medium 862 
(Gibco) plus Ham’s F12 NUT-MIX (Gibco) medium in a 1:1 ratio, 863 
supplemented with Glutamax-I, chemically defined lipid concentrate (Life 864 
Technologies), transferrin (15 μg/ml, Roche Diagnostics), insulin (7 μg/ml, 865 
Roche Diagnostics) and monothioglycerol (450 μM, Sigma). hiPSC were 866 
induced to differentiate into endoderm using CDM with with polyvinyl alcohol 867 
(PVA, 1 mg/ml, Sigma) with 100 ng/mL Activin, 10 ng/mL bone morphogenetic 868 
protein 4 (BMP4), 20 ng/mL FGF2, 10 μM phosphoinositide 3-kinase (PI3K) 869 
inhibitor Ly (LY294002) and 3 μM glycogen synthase kinase3 inhibitor 870 
CHIR99021 61. To obtain mesoderm precursors, hiPSC were grown for the 3 871 
following days in CDM-PVA in 20 ng/mL FGF2, 10 ng/mL BMP4 and 10 μM 872 
LY294002. Ectoderm was obtained using 1 µM Retinoic Acid (RA) and 25 873 
ng/ml BMP4 (R&D Systems). 874 
The efficiency of differentiation into the three germ layers was tested for 875 
expression of specific markers (SOX17, BRACHYURY and PAX6; 876 
Supplementary Table 3) by RT-PCR and immunostaining (SOX17, 877 
BRACHYURY and SOX1; Supplementary Table 4). 878 
ii. SMC lineages differentiation 879 
Lateral mesoderm and paraxial mesoderm intermediate populations were 880 
generated according the protocol previously described 21. The neural crest 881 
population was derived using a modified version of the previously described 882 
protocol to generate neuroectoderm 25. For mesoderm subtype differentiation, 883 
we differentiated the hiPSC to 36-h early mesoderm (FlyB) with a combination 884 
of FGF2 (20 ng/ml), LY294002 (10 μM) and BMP4 (10 ng/ml). Subsequent 885 
mesoderm subtype specification was further obtained with FGF (20 ng/ml) 886 
and BMP4 (50 ng/ml) for lateral mesoderm (LM) and FGF (20 ng/ml) and Ly 887 
(10 μM) for paraxial mesoderm (PM) for a further 4 days. To produce neural 888 
crest (NC), we modified the previously described protocol for neuroectoderm 889 
differentiation obtained by using fibroblast growth factor 2 (FGF2, 12 ng/ml) 890 
and the activin/nodal inhibitor SB431542 (10 μM) and passaged the cells first 891 
at day 4 and then repeatedly in FGF2 and SB431542 (; Serrano F, Bernard 892 
WG, Granata A, Iyer D, Kim M; in submission). After obtaining the 893 
intermediate populations, cells were trypsinized and cultured in SMC differen-894 
tiation medium CDM-PVA containing PDGF-BB (10 ng/ml, Peprotech) and 895 
TGF-β1 (2 ng/ml, Peprotech) for at least 12 days (PT). For long-term cultures, 896 
SMCs were subsequently grown in MEM medium (Sigma M5650) containing 897 
10% fetal bovine serum (Sigma F7524) up to 10 passages. Each intermediate 898 
was tested for the expression of specific genes (NKX2.5 for LM, TBX15 or 899 
MEOX1 for PM and p75 for NC) by RT-PCR and immunostaining. 900 
TGF-1 ELISA 901 
hiPSC-SMC were cultured in serum-free medium for 24h. Levels of TGF-β1 in 902 
culture supernatant were estimated by using DuoSet Sandwich ELISA 903 
according to the manufacturer’s instructions (DY240-05; R&D System). The 904 
samples were treated with the activation reagent (1N HCl) for 10 min at room 905 
temperature followed by addition of the neutralization reagent (1.2 N 906 
NaOH/0.5 M HEPES). Treated samples were transferred to ELISA plates 907 
coated with the capture antibody overnight at 4°C and incubated for 2h at RT. 908 
After washing, samples were incubated with the detection antibody for further 909 
2h at RT. After washing, samples were incubated with Streptavidin-HRP for 910 
20 min at RT followed by the substrate solution for further 20 min at RT. The 911 
optical density of each well was measured using a microplate reader set to 912 
450 nm (Synergy). Recombinant human TGF-β1 was used as a standard. 913 
Apoptosis assays 914 
i. Caspases activity  915 
WT and MF SMC cells were harvested at the end of the differentiation 916 
protocol (PT day12; PTD12) and at mature stage (after one month culture in 917 
serum-containing media; S30). Cells were incubated with Cytofix/Cytoperm 918 
Fixation solution (BD Biosciences) for 20 min at 4°C, then washed with Perm 919 
Wash Buffer/PBS (BD Biosciences). Cells were treated for Caspases activity 920 
using the Vybrant® FAM Poly Caspases Assay kit (V35117; Invitrogen). The 921 
staining was done according to manufacture instructors.  SMC cells were 922 
trypsinised and the resuspension was incubated with FAM-488 for 1h at 37 923 
degrees. After a couple of washes, cells were incubated for further 10 minutes 924 
with PI (10g/ml) to visualize death cells.  925 
ii. AnnexinV assay 926 
For AnnexinV staining, 1X106 cells/ml were harvested and resuspended in 1X 927 
annexin-binding buffer and incubated with 5l of AnnexinV-488 (Alexa Fluor® 928 
488 Annexin V/Dead Cell Apoptosis Kit; Life technologies) for 15 minutes at 929 
RT. Cells were then resuspended in PBS and measured with a Beckman 930 
Coulter CyanADP cell analyzer. Flow cytometric data were analyzed with 931 
FlowJo VX software. 932 
 933 
Cell Proliferation Assay  934 
i. MMT assay 935 
Triplicate samples of 5 × 103 hiPSC-SMC were cultured in a 96-well microtiter 936 
plate in MEM with or without serum for 72 h. Cell proliferation was measured 937 
by the CellTiter® 96 Non-Radioactive Cell Proliferation Assay Kit (G4000; 938 
Promega), according to the manufacturer's recommendations. After 939 
incubation with the chromogenic solution for 1h at 37°C, the rate of formazan 940 
dye formation was determined by measuring the absorbance at 570 nm. The 941 
value of the proliferative cells was expressed relative to the basal value 942 
(serum-starved non proliferative cells).  943 
ii. BrdU assay 944 
For BrdU labelling, hiPSC-SMC were treated with BrdU (10; BD 945 
Bioscience) overnight before collection. Cells were fixed with PFA 4% 946 
(Affymetrix) and blocked with 3 % BSA/0.5% Triton-X100 in PBS for 20 min at 947 
RT. Cells were then treated with 1.5M HCl for 30 min at RT and stained with 948 
an anti-BrdU antibody (1:50, Becton Dickinson) overnight at 4°C. The 949 
following day, the cells were incubated with a secondary Alexa FITC-tagged 950 
secondary antibody (1:500, Molecular Probes Invitrogen) and DAPI (10 μg/ml, 951 
Vector Laboratories) for 1h at RT. The numbers of BrdU-positive cells and 952 
total cells were counted in a blinded manner and divided by the total number 953 
of cells (DAPI stained nuclei). 954 
Calcium Fluo4-AM assay and contraction study 955 
SMCs were preloaded with the calcium-sensitive fluorophore Fluo-4 AM (2.5 956 
μM, Molecular Probes) in normal extracellular solution (NES; 140 mM NaCl, 5 957 
mM KCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM glucose and 10 mM HEPES, pH 958 
7.3) for 1 h at RT. Cells were the washed for 15 min at RT. Intracellular 959 
calcium flux was monitored as time series with acquisition rates of 1 frame 960 
every 0.2ms over a period of 1 min using a Zeiss LSM 700 confocal 961 
microscope, before and after addition of carbachol (100 μM, Sigma). The total 962 
Fluo4-AM uptake was measured by treating the cells with 0.1% Triton to 963 
permeabilise the cellular membranes. For both WT and MF SMCs, ten cells 964 
were randomly picked from a field of view and the fluorescent trace was 965 
analysed using ImageJ software.  966 
FITC-gelatin degradation assay 967 
 Cells were plated into m-slide 8 glass bottom wells (Ibidi) previously coated 968 
with FITC-gelatin (1mg/ml; Life Technologies G13187), air dried, rehydrated 969 
with water for 15 min and fixed with glutaraldehyde for 30 min. Cells were 970 
grown on FITC-gelatin-coated wells for 48h and then fixed with 4% PFA, 971 
permeabilised with 0.5% Triton X-100, washed twice with PBS and blocked in 972 
1% FBS blocking solution. Cells were then stained with a CNN1 specific 973 
antibody (1:2000; Sigma) overnight at 4°C followed by Alexa Fluor 588-tagged 974 
secondary antibody (1:500, Molecular Probes Invitrogen) and DAPI (10 μg/ml, 975 
Vector Laboratories) for 1h at RT. Fluorescence intensity was analysed with 976 
ImageJ software and expressed as relative to cell numbers (DAPI staining). 5 977 
images were taken for each well of each of the three independent. The results 978 
are presented as means ± SD of three independent experiments. 979 
Immunofluorescence staining of hiPSC, intermediates and SMCs 980 
Adherent cells were fixed with 4% PFA, permeabilised with 0.5% Triton-X100 981 
(Sigma) in PBS and blocked with 5 % serum/PBS for 1h at RT.  982 
The full list of primary antibodies used is provided in Supplementary Table 4.  983 
hiPSC were incubated with primary antibodies: OCT3/4, SOX2, TRA-1-60 and 984 
SSEA4 overnight at 4°C. Intermediate populations were stained with primary 985 
antibody specific for LM (NKX2.5), PM (MEOX1) and NC (p75). SMC were 986 
stained for SM markers, using primary antibodies for CNN1 (1:20,000, 987 
Calponin1, Sigma) and ACTA2 (1:500, smooth muscle -ACTIN, Sigma) 988 
overnight at 4°C.  989 
The 3 germ layers derived from hiPSC were stained using the Human Three 990 
Germ Layer 3-Color Immunocytochemistry Kit (SC022; R&D System).  991 
In WT and MF SMC, fibrillin 1 was detected in the extracellular matrix using a 992 
specific monoclonal antibody (1:400, Millipore) and Collagen Type I using a 993 
polyclonal antibody against subunit 1 (1:200; R&D System). For cytoskeletal 994 
and focal adhesion analysis, cells were stained with CytoPainter Phalloidin-995 
iFluor 488 (1:200; Abcam) and anti-Vinculin antibody (1:100; Sigma) 996 
respectively. The cells were then stained with Alexa Fluor-tagged secondary 997 
antibodies (1:500, Molecular Probes Invitrogen) and DAPI (10 μg/ml, Vector 998 
Laboratories) for 1h at RT.  999 
Images were taken with a Zeiss Axioplan microscope equipped with an 1000 
Axiocam HRc digital camera. Fibrillin-1 staining was quantified using ImageJ 1001 
software and expressed as relative to cell numbers (DAPI staining). 5 images 1002 
were taken for each well of each of the three independent experiments done 1003 
for each condition. The results are presented as means ± SD of three 1004 
independent experiments. 1005 
Immunofluorescence staining of human tissues 1006 
Aortic tissues were obtained by Priya Sastry, Research Fellow at Papworth 1007 
Hospital (project ID: 130372). The research was approved by NRES 1008 
Committee East of England and informed consent was obtained from all the 1009 
patients. The frozen tissues were sectioned and fixed with 4% PFA, 1010 
permeabilised with 0.5% Triton-X100 in PBS and blocked with 5 % 1011 
serum/PBS for 1h at RT. Section were incubated with anti-KLF4 (1:200; 1012 
Abcam) or anti-phospho-p38 (1:200, R&D System) and ACTA2 (1:200) 1013 
antibodies. Afterwards, sections were incubated with Alexa Fluor-tagged 488 1014 
and 568 secondary antibodies for 1h at RT. Sections were then washed with 1015 
PBS and mounted with VECTASHIELD-DAPI mounting medium (VECTOR 1016 
Laboratories). The numbers of KLF4 or P-p38-positive cells were counted in a 1017 
blinded manner and divided by the total number of ACTA2 positive-cells. The 1018 
results are presented as means ± SD of two independent experiments.1019 
Luciferase assays 1020 
i. MLECs (Mink lung epithelial cells) PAI-1 reporter 1021 
MLCEs stably transfected with an 800bp fragment of the 5’ promoter end of 1022 
the human PAI-1 gene, fused to the luciferase gene (4 ×104 cells) were plated 1023 
into a 96-well plate with DMEM supplemented with 10% FBS and 200g/ml 1024 
G418. The day after, MLCEs were treated with conditioned media from WT 1025 
and MF SMC for 12h. Control cells were left untreated. After, MLCEs were 1026 
lysate with 20l of Passive Lysis Buffer 1X (Luciferase system; Promega 1027 
E1501). Luciferase assay reagent (100 μl: Promega) was added to each well 1028 
by injector and the relative luciferase unit (RLU) was read by 2030 Multilabel 1029 
Reader (Perkin Elmer). 1030 
ii. SBE4 Reporter Luciferase assay 1031 
SMC were plated into a 24-well plate and transfected with SBE4-Luciferase 1032 
reporter vector (Addgene plasmid #164965; 200 ng) using Lipofectamin2000 1033 
(Life Technologies), following manufacturer instructions. On day 2 after the 1034 
transfection, SMC were serum-starved. After 24 hours, SMC were treated with 1035 
15 g/ml of TGF or 5 g/ml of anti-TGF blocking antibody or Losartan 1036 
(1M) for 12 hours. Control cells were kept in serum-free media. After, SMC 1037 
were lysed with 60l of Passive Lysis Buffer 1X and transferred in triplicates 1038 
into a 96-well plate. Luciferase assay was performed and RLU was measured 1039 
as previously described. The results are the mean ± SD of three independent 1040 
experiments. 1041 
Cyclic Strain 1042 
SMC were plated on silicone elastomer–bottomed culture Collagen I, 1043 
precoated plates and grown for 2 up to 7 days, and subjected to cyclic strain 1044 
with a Cyclic Stress Unit (FX5000 Tension System, Flexcell International 1045 
Corporation). Cyclic sine wave deformation (60 cycles/min) and 10% 1046 
elongation were applied for 24h previous to cells harvesting for RNA analysis. 1047 
Static stretching 1048 
500µm-thick polydimethylsiloxane (PDMS) membranes were produced using 1049 
spin-coating of silicon wafers (Christophe Verstreken at the Cambridge Stem 1050 
Cell Institute). These were functionalised using plasma treatment and UV 1051 
exposure of sulfo-sanpah (Thermo-Fisher), and incubated with collagen IV 1052 
(Corning) overnight. NC-SMC were seeded onto the membranes at a density 1053 
of 2x10^5 and left to attach for 4hrs at 37ºC. The membranes were stretched 1054 
20% uniaxially overnight using a custom-made device, while controls were left 1055 
unstretched. Membranes were washed three times with PBS, fixed with PFA 1056 
4% for 15 min, washed with PBS and permeabilised using a blocking buffer 1057 
(0.5% Triton X-100) for 1hr at RT. Incubation with primary antibodies anti-1058 
vinculin antibody (1:100; Sigma) overnight at 4°C, was followed by 1059 
incubations with Alexa Fluor-tagged 568 and CytoPainter Phalloidin-iFluor 1060 
488 (1:200; Abcam) and DAPI for 1h at RT. Membranes were washed three 1061 
times with PBS for 5min and were mounted using ProLong Gold (Thermo-1062 
Fisher).  1063 
TGF-β neutralizing antibody and inhibitors treatment 1064 
SMC cells at stage PT d12 or after one-month culture in serum-containing 1065 
media (S30), were treated for a week with different inhibitors, which are listed 1066 
in Supplementary Table 5. Samples were processed for fibrillin-1 1067 
immunostaining analysis and RT-PCR analysis as described above. 1068 
KLF4 siRNA gene silencing  1069 
KLF4 knockdown was carried out using KLF4 Silencer Select from Ambion 1070 
(siRKLF4; ID517793). A nonspecific siRNA (siScr; AllStars Negative control, 1071 
Qiagen) was used as a negative control. hiPSC-derived SMCs were 1072 
transfected with siRNA (20 nM for 1 well of 6-wells plate) using DharmaFECT 1073 
transfection reagent (Thermo Scientific Dharmacon). The transfection was 1074 
repeated after 2 days and the mRNA and protein analyses were done after 1075 
24h and 48h respectively. The efficiency of KLF4 knockdown by siRNA was 1076 
approximately 90%. 1077 
 1078 
Statistical Analysis 1079 
The results in the figure legends are presented as the mean ± SD of three 1080 
independent replicates. Statistical differences between the means were 1081 
examined by Student’s t test, two-sided. *P < 0.05 was considered statistically 1082 
significant.  1083 
Pre-specified effect size was not defined. Between 2 to 5 independent 1084 
samples for experiments were used and estimates of normality were not 1085 
necessary. 1086 
 1087 
See Supplementary Notes for Teratoma Formation, RNA Isolation, Reverse-1088 
Transcriptase Polymerase Chain Reaction and Quantitative PCR Analysis, 1089 
Western blotting Analysis, Transmission Electron microscopy (TEM), Flow 1090 
cytometric analysis and Antiplasmin viability assay. 1091 
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